References
- Vajo Z, Fawcett J, Duckworth W. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocrine Reviews 2001;22(5): 706–17.
- Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. The Cochrane Database of Systematic Reviews 2006;
- Seibenhofer A, Plank J, Berghold A, et al. Meta-analysis of short-acting insulin analogues in adult patients with Type 1 diabetes: continuous subcutaneous injection versus injection therapy. Diabetologia 2004; 47: 1895–905.
- Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin Aspart. Diabetes Care 2003; 26: 590–6.
- Ratner RE, Hirsch IB, Neifing JL. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639–43.
- Garg SK, Gottlieb PA, Hisatomi ME. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004; 66: 49–56.
- Chase HP, Dixon B, Pearson J, et al. Reduced hypoglycemic episodes and improved glycemia control in children with type 1 diabetes using insulin glargine and neutral protamine hagedorn insulin. J Pediatr 2003; 143: 737–40.
- The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
- Diabetes control and complications trial research group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr 1994; 125: 177–88.
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of diabetes control and complications trial. J Pediatr 2006; 139: 804–12.
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563–9.
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643–53.
- International Society for Pediatric and Adolescent Diabetes (ISPAD). 2000 consensus guidelines for the management of type 1 diabetes mellitus in children and adolescents. Available: www.ispad.org